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The ageing population continues to suffer from its primary killer, cardiovascular disease 
(CVD). Despite recent advances in interventional medicinal and surgical therapies towards 
the end of the 20th century, the epidemic of cardiovascular disease has not been halted. 
Yet, rather than receding globally, the burden of CVD has risen to become a top cause 
of morbidity and mortality worldwide. Most CVD arises from thrombotic rupture of an 
atherosclerotic plaque, the pathologic thickening of coronary and carotid artery segments 
and subsequent distal ischemia in heart or brain. In fact, one-fifth of deaths are directly 
attributable to thrombotic rupture of a vulnerable plaque. Atherosclerotic lesion formation 
is caused by a concert of interactions between circulating leukocytes and platelets, 
interacting with the endothelial barrier, signalling into the arterial wall by the release of 
cytokines and extracellular vesicles (EVs). Both platelet- and cell-derived EVs represent a 
novel mechanism of cellular communication, particularly by the transport and transfer of 
cargo and by reprogramming of the recipient cell. These interactions result in phenotypic 
switching of vascular smooth muscle cells (VSMCs) causing migration and proliferation, 
and subsequent secretion of EVs. Loss of VSMCs attracts perivascular Mesenchymal 
Stem Cells (MSCs) from the adventitia, which are a source of VSMCs and contribute 
to repair after vascular injury. However, continuous stress stimuli eventually switch 
phenotype of cells into osteochondrogenic VSMCs facilitating vascular calcification. 
Although Virchow’s triad is over 100 years old, it is a reality that is accurate today. It can 
be briefly summarised as changes in the composition of blood (platelet EVs), alterations 
in the vessel wall (VSMC phenotypic switching, MSC infiltration and EV release) and 
disruption of blood flow (atherothrombosis). In this paper, we review the latest relevant 
advances in the identification of extracellular vesicle pathways as well as VSMCs and 
pericyte/MSC phenotypic switching, underlying vascular calcification.
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extRaCellulaR veSiCleS
Extracellular vesicles (EVs) are currently considered as important 
physiological players. Their secretion represents a universally 
active cellular function in all living organisms from bacteria to 
humans (1). EVs are highly heterogeneous structures that differ 
in size, biochemical content and mode of secretion. Current 
nomenclature distinguishes three populations of EVs: (1) exosomes 
(30–100 nm), which originate when multivesicular bodies fuse with 
the plasma membrane, (2) microvesicles/ectosomes (100–1,000 
nm), which are generated by budding of the plasma membrane and 
(3) apoptotic bodies (>1,000 nm), which are formed in the process 
of programmed cell death (2–5). Each family is composed of small 
phospholipid membrane-enclosed entities released spontaneously, 
or, in response to cell activation or apoptosis (6). EV release is 
stimulated via multiple physiological and pathological conditions, 
making them potential diagnostic biomarkers for monitoring 
various diseases (7). Their presence has been detected in a number 
of bodily fluids from healthy individuals, such as peripheral blood, 
urine, saliva and synovial fluid to name a few (1, 8, 9). In terms of 
pathological states, first breakthroughs in the field of EV research 
were made in oncology and immunology, yet today cardiovascular 
disease represents one of the most intensively studied and rapidly 
developing areas of the extracellular vesicle field (4). The number of 
circulating EV levels has been shown to be associated with various 
cardiovascular and metabolic disorders, including atherosclerosis 
and diabetes mellitus (8). In the vasculature, EVs are released from 
platelets, endothelial cells, smooth muscle cells, erythrocytes and 
leukocytes (6, 7).
Platelet-Derived extracellular vesicles
EVs from platelets were first described in 1967 by Peter Wolf 
from human blood samples, where they were originally referred 
to as “platelet dust” (10). Further studies demonstrated that EVs 
are released when platelets attach to the vessel wall (11). Later 
it was reported that platelet-EVs are composed of two different 
types: exosomes and microvesicles (12). Since then platelet EVs 
have been shown to be involved in several processes in the human 
body, such as coagulation and atherosclerosis (13). Given that EVs 
express phospholipids on their surface, they are capable of binding 
(activated) coagulation factors. Interestingly, their coagulation 
activity is 50–100 times higher compared to activated platelets 
(14). In fact, a genetic disorder that is associated with deficient 
EV formation by platelets leads to bleeding (15). This suggests that 
promotion of coagulation by EVs is an important physiological 
mechanism (6).
On the other hand, platelet EVs are known to accumulate in 
platelet concentrates (16). Transfusion of platelet concentrates is 
associated with adverse reactions in the recipient, more often than 
any other blood-derived product (17). This might be explained 
by the fact that platelet EVs are rich in inflammatory molecules 
(e.g., CD40L), so they can adhere to leukocytes by CD62P – 
PSGL-1 interactions and transport pro-inflammatory signals. 
Several studies have demonstrated that platelet EVs isolated from 
platelet concentrates can modulate the phenotype and activities of 
leukocytes and vascular cells (see below). Platelet EVs retain many 
properties of their parent cells, such as the presence of surface 
specific antigens (Table 1), the ability to deposit chemokines to 
the vessel wall and to confer inflammatory signals to distal sites 
(28). In human blood, platelet-derived EVs are the most abundant 
population of EVs, despite the fact that erythrocytes are about 30 
times more numerous than platelets (29). It has been estimated that 
in circulation 70–90% of all EVs are derived from platelets, 10% 
originate from granulocytes and only 5% come from endothelial 
cells, red blood cells and monocytes (1). The number of circulating 
platelet EVs is also influenced by cardiovascular medication. 
Antiplatelet agents, antihypertensive agents and cholesterol-
lowering drugs inhibit EV release from platelets (30, 31). However, 
in studies on patients treated with statins, consensus on the number 
of circulating platelet EVs has not been established (30, 32). Of 
note, it has been proposed that the majority of the circulating 
CD41-positive EVs actually originate from megakaryocytes, rather 
than from platelets (33). In addition, platelet-derived EVs might 
be distinguished from their megakaryocyte-derived counterparts 
through the detection of surface molecules such as CD62P, 
LAMP-1, CLEC-2 and GPVI.
vascular inflammatory Functions of 
Platelet-Derived evs
Besides the involvement of platelet-derived EVs in the coagulation 
process, evidence also points towards a role in immune- and 
inflammation-related processes. For example, platelet-derived 
EVs have been shown to influence vascular cells (endothelial cells 
and smooth muscle cells) and leukocytes, thereby changing their 
phenotype and function. EVs are considered to play an important 
role in cell-cell communication, their membrane-enclosed 
content, small size and repertoire of surface receptors facilitate 
long distance transport within bodily fluids (5, 8, 34). EVs can 
influence target cells by providing ligands which augment the 
secretion of growth factors or cytokines, transfer of cell adhesion 
molecules or reprogram target cells through their genetic make up 
(1, 28, 29). When isolated platelet EVs are incubated with 
table 1 |  Surface markers found on platelet EV.
Cluster of differentiation 
(CD) or abbreviation
trivial or full name Reference
CD9 Tetraspanin-29 (18)
CD29 Integrin β1 (19)
CD31 PECAM-1 (19)
CD36 Platelet GPIV (20)
CD42a Platelet GPIX (21)
CD42b Platelet GPIbα (19, 22)
CD63 Tetraspanin-30 (19)
CD59 Membrane attack complex inhibition 
factor
(20)
CD61 Integrin beta 3 (22)
CD154 CD40 Ligand (23, 24)
CD184 CXCR4 (23)
PAR-1 Protease-activated receptor-1 (23)
CD321 Junctional adhesionmolecule-A (25)
TSP-1 Thrombospondin-1 (21)
VN Vitronectin (26)
VWF Von Willebrand Factor (27)
Schurgers et al.
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monocytes, platelet EVs readily bind to monocytes and phagocytic 
uptake of platelet EVs can be observed over time (35). In chemotaxis 
assays, monocytic cells are actively attracted by platelet EVs, an 
effect that can be blocked by antibodies against CCL5. Prolonged 
incubation of monocytes with platelet EVs results in a notable 
change of surface marker expression, indicating a polarisation 
of the monocytes to M2-type macrophages (35). Finally, platelet 
EVs were found to induce the secretion of TNFα from monocytic 
cells more strongly than platelets, whereas incubation with 
platelets led to a robust release of GM-CSF (35). Similar studies 
have demonstrated that platelet EVs induce the differentiation 
of macrophages into dendritic cells (20) and that platelet EVs 
are even able to “reprogram” the gene expression profile and 
function of macrophages (36). Although platelet EVs are present 
both in diseased patients and healthy subjects, increased levels 
have been associated with various pathological disorders, such as 
atherosclerosis and diabetes mellitus (Table 2).
Pathological remodelling of the vasculature involves an 
intricate and dynamic interaction between blood cells (platelets, 
leukocytes), vascular cells (endothelial cells, smooth muscle cells 
and adventitial cells) and their direct microenvironment (66). 
EV-mediated signalling between hematological cells and vascular 
cells is also of importance in this process. Elevation of platelet 
EVs in cardiovascular disease appears to be a common process, 
their interaction with the vascular endothelium has been an area 
of high interest. However, current knowledge in this field is still 
very limited and our understanding relies mainly on in vitro 
experiments. The importance of leukocyte-endothelium signalling 
in pathophysiological conditions of the vasculature is already well 
known. More recently the role of platelet EVs in these processes 
has been demonstrated. In vitro experimentation has shown that 
shear stress-activated platelet EVs facilitate the interaction between 
monocytes and endothelial cells. This is facilitated by increases in 
inflammatory cytokine levels and cell adhesion molecules on both 
cell types (67). Another study indicated that platelet EVs contain 
bioactive lipids (e.g., arachidonic acid), that stimulate ICAM-1 
expression in HUVECs, leading to enhanced monocyte-endothelial 
interactions (68). Platelet EVs may also activate endothelial cells 
and leukocytes, more specifically, neutrophils by surface molecules 
CD41 and CD62P, further demonstrating their importance in 
modulating inflammation (69). It has been also shown that platelet 
EVs can deposit inflammatory molecules such as CCL5 (RANTES) 
during rolling interactions over endothelial cell monolayers, 
facilitating the subsequent recruitment of monocytes (25). In this 
study, rolling interactions depended on P-selectin and GPIb, while 
transfer of CCL5 was dependent on integrin αIIbβ3 and junctional 
adhesion molecule A (25).
Interestingly, more than 700 miRNAs have been found to be 
stored in platelets (70). Platelets also can contain the functional 
miRNA processing machinery required for the processing of 
miRNA precursors (71). Moreover, evidence is accumulating that 
platelets and platelet-EVs can horizontally transfer nucleic acids 
to endothelial cells (72, 73). Platelet EVs isolated from activated 
platelets contain significant amounts of miRNA, further to this, 
functional transfer of miRNA from platelets to endothelial cells 
was found to occur through vesicle formation (74, 75). Uptake of 
platelet EV-associated miRNA results in modulation of endothelial 
target gene expression demonstrated by a downregulation of 
ICAM-1 (72).
Besides the endothelial lining of the vessel wall, VSMCs can 
also be influenced by platelet EVs. Platelets can adhere directly to 
VSMCs, facilitated by the interaction of CX3CR1 on platelets with 
CX3CL1 on VSMCs (76). Although platelets do not make contact 
with VSMCs under healthy conditions, such encounters might 
occur after vascular damage, increased endothelial permeability or 
through intraplaque haemorrhage. Upon endothelial denudation, 
platelets in a thrombus might release EVs that then come in contact 
with VSMCs. Increased permeability of the endothelial lining 
might permit the passage of circulating EVs and during intraplaque 
haemorrhage, EVs might be formed due to platelet contact with 
the highly thrombogenic plaque interior. On the other hand, a 
study investigating EVs isolated from atherosclerotic plaques did 
not observe a significant fraction of platelet-EVs within plaque 
(77). It is possible that platelet-EVs lose their surface markers by 
enzymatic shedding after activation (78), that platelet-EVs are 
rapidly phagocytosed by macrophages (35, 36), or that platelet-
EVs indeed constitute only a minor fraction of the total EV content 
within a plaque. Nevertheless, a potential influence of platelet EVs 
on the behaviour and phenotype of VSMCs was investigated in 
our recent work. Binding studies using CFSE-labelled platelet EVs 
and VSMCs revealed that the platelet EV–VSMC interaction is 
metal ion-dependent and that αIIbβ3 on platelet EV is the primary 
receptor that mediates interactions with VSMCs (79). Platelet 
EVs induce migration and proliferation of VSMCs in a CXCL4-
dependent manner. Prolonged incubation of VSMCs with platelet 
EVs results in an increased adhesiveness for THP1 monocytic 
cells under flow conditions and an increase in interleukin 6 
production, indicating that platelet EVs have pro-inflammatory 
effects on VSMCs. Interestingly, the incubation of cultured VSMCs 
with platelet EVs led to a phenotypic switch towards a synthetic 
phenotype, as evidenced by morphological changes and a reduced 
expression of the contractile marker calponin (79). Although 
direct contact of VSMCs with platelet EVs leads to changes in 
proliferation, migration, marker expression and phenotype of 
VSMCs, the possibility exists that platelet EVs might alter the 
behavior of surrounding cells e.g., the endothelium, thereby 
indirectly affecting VSMCs by released factors or the transfer of 
table 2 |  Cardiovascular/metabolic diseases associated with increased 
platelet-EV levels.
Disorder Reference
Hypercholesterolemia and subclinical atherosclerosis  (37)
Coronary calcification (38)
Carotid atherosclerosis (39)
Coronary heart disease (40)
Acute coronary syndrome   (41–44)
Peripheral arterial disease   (45–48)
Hypertension (49, 50)
Venous Thrombo-embolism (51, 52)
Stroke  (53–55)
Diabetes mellitus   (56–59)
Metabolic syndrome and obesity   (60–63)
Table dapted from Aatonen et al. (64) and Ridger et al. (65)
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endothelial EVs, analogous to what has been observed during 
abnormal shear stress (80).
Taken together, platelet EVs influence both phenotype and 
behaviour of leukocytes and vascular cells, thus are important 
initiators and propagators in vascular remodelling and downstream 
processes, such as calcification.
initiation and Propagation of vascular 
Calcification is Regulated by vascular 
Smooth Muscle Cell Function
Vascular smooth muscle cells (VSMCs) are the most abundant cell 
source of the vasculature. Unlike most cells, VSMCs arise from several 
lineages (81). They are critical to maintaining structure and function 
of the vascular system (82). Their role is central to vessel dilation 
and constriction as well as vessel remodelling. VSMCs produce 
components of the vascular extracellular matrix (ECM), therefore 
altering the composition of connective tissue and can increase 
the number of VSMCs present in the vasculature by proliferating. 
VSMCs are commonly considered to be heterogeneous, having 
either contractile or non-contractile (synthetic) properties (83). This 
heterogeneity is present in both developing and adult vasculature and 
is the most defining feature of VSMCs. It has been hypothesised that 
the different characteristics and functions of VSMCs originate from 
early developmental cues, as well as spatiotemporal gene regulation 
of differentiation markers (84).
While in a contractile state, VSMCs contract and relax to 
enable blood flow around the body. In this contractile state, they 
express highly VSMC-specific markers for contractility such as 
SM-αA, calponin and SM22α. These cells have low motility, hence 
decreased cellular migration is observed, as well as decreased levels 
of proliferation and a reduced production of extracellular matrices. 
This enables the blood vessels to maintain elasticity allowing proper 
function and delivery of blood supply to the anatomy. When synthetic, 
VSMCs exhibit a marked decrease in expression for VSMC-specific 
contractility markers, but express more highly markers for matrix 
metalloproteinase, collagenase, osteopontin and an increase in 
production of EVs. Phenotype switching enables VSMCs to maintain 
blood flow as well as support the vascular niche. During vessel repair, 
migration and proliferation of VSMCs is necessary. Additionally, 
increases in expression of growth factors such as PDGF, TGF and 
VEGF, as well as an increased production of ECM is required to 
reconstruct vasculature following injury.
vascular Smooth Muscle Cell Phenotypic 
Switching
Terminal differentiation of VSMCs is not a definitive end and it is 
possible to switch between phenotypes depending on the demand 
of the vascular niche. Contractile VSMCs are generally referred 
to as quiescent differentiated cells, whereas the synthetic state is 
associated with plasticity and appropriately referred to by some as 
dedifferentiated VSMCs. Several pathologies of the vasculature are 
associated with VSMC phenotype switching such as atherosclerosis, 
restenosis, aneurysm and calcification (85–87). Vascular calcification, 
the deposition of hydroxyapatite crystals along the vessel, decreases 
vessel flexibility, impairs proper blood flow and is associated with 
cardiovascular disease mortality (88).
While culture conditions for in vitro maintenance of human 
VSMCs in either synthetic or contractile phenotypes have been 
identified, the precise mechanisms that enable VSMC phenotype 
switching remains unknown (89). Literature has sparse number 
of papers implicating miRNAs and proteins in either maintenance 
or inducing VSMC phenotype switch (90). Furthermore, several 
identified miRNA and proteins have been eluded to modulation of 
vascular pathologies associated with VSMC phenotype switching or 
a dysregulation in phenotype switching (90). During pathological 
phenotypic switching, VSMCs can adapt an osteogenic, chondrogenic 
or inflammatory phenotype (91–93).
Adding further interference to the quandary of VSMC phenotype 
switching, wall resident adventitial progenitor cells have been recently 
implicated as vessel wall regulators (94, 95). Adventitial progenitors 
have been found to differentiate into osteoblasts, chondrocytes, 
adipocytes, macrophage as well as VSMCs. This has led to the 
hypothesis that adventitial progenitor cells are master regulators of the 
vascular niche. When progenitor dysfunction occurs, differentiation 
of VSMCs to an osteoblastic, chondrogenic or macrophage-like 
capacity are formed. This is yet to be fully appreciated.
vSMC-Derived extracellular vesicles
In 1967, Anderson first used the name “matrix vesicles” in cartilage 
development and calcification (96). Tanimura and co-workers 
were the first to report an association between small membrane 
encapsulated particles, matrix vesicles, and vascular calcification (97). 
Vesicular structures have been found in both intimal and medial 
layers and are likely derived from VSMCs. The release of EVs from 
VSMCs was first described as a rescue mechanism against calcium 
overloading, in an attempt to prevent apoptosis (98).
Today, it is appreciated by many that the role of EVs released by 
VSMCs is significant in VSMC phenotype switching and calcification. 
VSMCs have been found to release a variety of EVs when in either 
synthetic or osteogenic phenotype. A group of VSMC EVs have 
been identified and somewhat characterised by tetraspanin markers 
CD9, CD63 and CD81 (99). Furthermore, EVs share similarity to 
osteoblast EVs, having calcium binding capacity and osteoblast-like 
ECM production. Interestingly, calcific conditions in vitro increase 
expression of SMPD3 and subsequent EV genesis. Inhibition of 
SMPD3 completely ablates generation of EVs and calcification. 
Additionally, in vivo identification of CD63 with calcification of 
vessels of chronic kidney disease (CKD) patients implicates that 
SMPD3 is a potential novel therapeutic target to inhibit EV genesis 
and thus vascular calcification.
Chen and associates recently identified a novel role between 
VSMCs and EVs in calcification (100). Initially they characterised 
EVs from four sources, two from cellular-derived EVs the others from 
matrix vesicles. Curiously, they identified that both populations of 
cellular-derived EVs possessed the capacity to enhance calcification, 
however matrix vesicles did not possess this ability, even though all 
four EV types were uniformly endocytosed by VSMCs. They eluded 
to novel increases in expression for MEK1, Erk1/2, Nox1 and SOD2 
alongside increases in intracellular calcium ion content, EV biogenesis 
and calcification. All EVs were found to express tetraspanins CD9, 
CD63 and CD81, however, the proportion of expression differed 
significantly between the media and cellular EVs. Cellular-derived 
Schurgers et al.
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EVs expressed more significantly for CD63 that strikingly coincides 
with Kapustin et al. in vivo observation of CD63 co-localisation with 
calcification in calcified CKD vessels (99).
Differences between mineralising and non-mineralising EVs 
were first revealed by Kirsch et al. within chondrocytes, where they 
identified high expression of annexin A5 within calcifying EVs (101). 
The precise function of annexins in calcification has not been fully 
unravelled (102). Regarding in vitro VSMC calcification, annexin 
A2 has been highlighted in calcium regulation resulting in VSMC 
EV generation (103). Annexin A2 may bind to fetuin-A on the cell 
membrane of VSMCs, this is in turn internalised by endocytosis 
preventing fetuin-A from blocking mineral formation. Increases of 
annexin A2, annexin A5 and alkaline phosphatase co-localisation 
are proportional to decreases in fetuin-A expression within in vitro 
VSMC calcification models. Macrophage-derived EV calcification is 
induced via binding of annexins A2 and A5 to phosphatidylserine 
(PS) (104). Annexin A5 with S100A9 binding to PS is critical for 
osteoblast-derived ECM production, interestingly this mechanism 
also occurs during macrophage production of calcifying EVs. Further 
interrogation of annexins A2, A5 and A6 in VSMC calcification, 
phenotype modulation and EV genesis will add to our understanding 
of the roles of annexins in the cellular context of VSMCs.
Propagation of calcification via vitamin K-antagonist (VKA) 
treatment led to the identification of matrix Gla-protein (MGP) as 
a potent calcification inhibitor (105). Twenty years have now passed 
since MGP inhibitory action was identified, ten years since the 
mechanism of MGP activation was eluded to by means of serine 
phosphorylation and gamma-glutamyl carboxylation (91, 106, 
107). More recently it has been demonstrated that VSMC-derived 
EVs contain copious amounts of Gla-proteins from circulation 
(108). Prothrombin (PT), like MGP, contains a Gla domain. It has 
been recently demonstrated that production of calcifying VSMC-
derived EVs can be inhibited by PT interaction. The Gla domain 
of PT interacts with the surface of EVs, preventing nucleation sites 
for calcification (108). This finding has been substantiated by the 
localisation of PT in calcified regions of the iliac/femoral arteries 
from a cohort of patients with CKD. Furthermore, circulating levels 
of PT are reduced in patients with vascular calcification. Accordingly, 
in absence of MGP, VSMC-derived EVs act to induce calcification, 
suggesting a potential novel role for inhibition of calcification via 
PT-EV interactions.
Recent findings have implicated a key role for Sortilin in VSMC 
calcifying EV biogenesis and release. Originally, Sortilin 1 was 
identified as driving factor in EV-facilitated calcification through 
FiguRe 1 |  VSMC with Sortilin, MGP and annexin production of calcifying EVs.
6 April  2018 | Volume 5 | Article 36Frontiers in Cardiovascular Medicine | www. frontiersin. org
Schurgers et al. Role of Extracellular Vesicles in Vascular Calcification
Rab11 interaction (109). More recently, it was shown that Sortilin 
1 localises in human calcifying vessels (110). In addition, Sortilin 
1 plays a role in VSMC calcification in vitro. Sortilin 1 contributes 
to vascular calcification via tissue nonspecific alkaline phosphatase 
(TNAP) although regulation of TNAP expression within VSMC 
calcification remains poorly understood. Notably, Sortilin 1 has 
been identified as a driver in generation of osteoblasts, while TNAP 
expression was unaffected. This eludes to a potential novel mechanism 
in the production of VSMC-derived calcifying EVs, which might be 
a unique mechanism in vascular calcification (Figure 1).
Characterisation of EV cargo has been standardised to falling into 
either protein, RNA or lipid (111). The composition of lipid content 
in circulating EVs might provide novel insights into mechanisms 
for VSMC calcification. RNA content of VSMC-derived EVs may 
be mRNA, miRNA, lncRNA or circRNA, with miRNA being the 
most characterised in VSMC phenotype modulation and calcification 
(112). RNA lie within the unique position of being both genotype and 
phenotype which gives them a role in cellular regulation and pathology 
(113). Potently a wide array of miRNAs have been implicated by a 
variety of mechanisms contributing to, or inhibiting the development 
of vascular calcification (Figure 2 and Table 3). MiRNAs which either 
induce VSMC to an osteoblast-like pro-calcific phenotype or inhibit 
associated phenotype and calcification. The specific mechanism of 
which has been reviewed elsewhere (133, 134). Although the role 
of miRNAs within vascular calcification is being unravelled, many 
miRNAs have been identified via RNA screening between normal 
and calcified VSMCs. The origin of miRNA source in a pathological 
context remains elusive and requires further investigation.
Whether there is cross talk of EVs from different facets of the 
vascular niche or if there is a dysregulation in VSMC maintenance 
remains an important question. Understanding the cross talk of EVs 
between vascular cells might be significant to appreciating the precise 
mechanisms for vascular calcification. MiR-206, ARF6 and NCX1 
have been identified as endothelial cell-released EV content capable 
of regulating VSMC contractile phenotype (135). Furthermore, given 
the observed increase of endothelial EV release following injury, it has 
been noted that endothelial cell EVs from human pulmonary artery 
not only interacted with pulmonary VSMCs, but interaction induced 
proliferation and had a seemingly anti-apoptotic effect on VSMCs 
(136). This suggests a direct pathological consequence of endothelial 
EV to VSMC crosstalk during and following intimal vessel injury.
MeSenChyMal SteM CellS aS 
PeRivaSCulaR PRogenitoRS
As described above, VSMCs are known to exhibit elaborate 
phenotypical plasticity and diversity during normal development, 
disease, and repair of vascular injury. The current theory of vascular 
calcification is that upon injury VSMCs dedifferentiate. VSMCs 
become synthetically active and under stress factors, like elevated 
FiguRe 2 |  Calcifying miRNAs in VSMC.
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calcium and phosphate levels or uremic toxins (e.g., during CKD), 
switch to a dedifferentiated synthetic phenotype and later become 
osteoblast like cells (99, 137). Genetic fate tracing strongly indicated 
mature VSMCs to be a major contributor to the development of 
atherosclerotic plaque remodeling (138). However, not all elements 
of plaque development and progression may be indicative as a result 
of VSMC phenotype switching. The fact, that atherosclerotic human 
vessels can contain complete trabecular bone with fully formed bone 
marrow sinusoids even containing hematopoietic cells is difficult to 
explain without new concepts, such as vascular stem cells. Indeed, the 
presence of a specialised progenitor population of VSMCs localised 
in the adventitia of muscular arteries has been suggested by several 
groups.
The perivascular niche houses pericytes, which are present at 
intervals along microcapilaries and pericyte-like cells are also located 
in the adventitia of large arteries. Peault and coworkers were the first 
to show that many pericytes are MSCs (139, 140). However, it remains 
elusive whether all pericytes are MSCs. A pericyte is defined as a cell 
that is completely or partially embedded in the endothelial basement 
membrane (141). The fact that MSCs are also located in the adventitia 
of large arteries distant from vasa vasorum and in the endosteal 
niche of the bone marrow indicates that not all MSCs are pericytes 
(94, 142). The recent evidence that the perivasculature represents 
the MSC niche explains why MSCs can be isolated from virtually all 
organs and tissues.
It was first described over 25 years ago that pericytes have an 
osteogenic potential (143) and subsequently pericyte-like cells with 
osteogenic capacity were isolated from VSMCs nodules of human aorta 
(144). A decade ago it has been reported that Sca1+/CD34+/PDGFRβ+ 
cells that reside in the adventitia of arteries possess a differentiation 
capacity towards smooth muscle cells and osteoblasts in vitro (145). 
Interestingly, these progenitors express the Hedgehog receptor Ptc1 
as well as most other hedgehog pathway members including Gli1-3 
(145). Other groups have reported that perivascular MSCs were also 
found to be progenitors of white adipocytes (146) follicular dendritic 
cells (147) and skeletal muscle (148), while also playing a major role 
in fibrotic response (149–151). Thus, various studies suggest the 
presence of adventitial MSC-like cells with osteogenic and myogenic 
potential. However, until recently the involvement of these MSC-like 
pericytes in cardiovascular disease development remained unclear.
Role of Perivascular MSC-like Cells in 
vascular Calcification
Using genetic labeling and in vivo fate tracing experiments it was 
recently revealed that the Hedgehog transcriptional activator Gli1 
specifically labels perivascular MSC-like cells (94, 142, 151, 152). Gli1+ 
cells reside in the pericyte niche with direct contact to endothelial cells 
of the microvasculature and in the adventitia of large arteries (94, 151). 
Gli1+ cells possess all criteria that have been used to define a MSCs 
including surface marker expression, tri-lineage differentiation and 
plastic adherence (94, 151). Inducible genetic fate tracing, the gold 
standard technique to dissect cellular hierarchies, indicated that Gli1+ 
cells are a major cellular source of myofibroblast in fibrosis of all major 
organs such as lung, kidney, liver, heart and bone marrow (142, 151).
The question is however, whether adventitial Gli1+ MSC-like 
cells are involved in acute injury repair and chronic vascular disease 
progression. Using in vivo genetic fate tracing, it was demonstrated 
table 3 |  MiRNA associated with phenotypic switching of VSMC.
Reference Calcifying miRna MiRna inhibiting 
Calcification
Paper
(114) 29b 133b, 211 MicroRNAs 29b, 133b and 211 regulate vascular smooth muscle calcification mediated by high 
phosphorous
(115) 32 MicroRNA-32 promotes calcification in vascular smooth muscle cells: implications as a novel marker for 
coronary artery calcification
(116) 3960, 2861 Runx2/miR-3960/miR-2861 positive feedback loop is responsible for osteogenic transdifferentiation of 
vascular smooth muscle cells
(117) 29 MiR-29-mediated elastin down-regulation contributes to inorganic phosphorous-induced osteoblastic 
differentiation in vascular smooth muscle cells
(118) 125b MiR-125b regulates calcification of vascular smooth muscle cells
(119) 135a MiR-135a suppresses calcification in sensence VSMCs by regulating KLF4/STAT3 pathway
(120) 204 MicroRNA-204 regulates vascular smooth muscle cell calcification in vitro and in vivo
(121) 221 + 222 MiRNA-221 and miRNA-222 synergistically function to promote vascular calcification
(122) 125b, 145, 155 Decreased microRNA is involved in the vascular remodelling abnormalities in chronic kidney disease (CKD)
(123) 762, 714, 712 Micro RNAs that target Ca(2 + transporters are involved in vascular smooth muscle cell calcification
(124) 30b, 30c Bone morphogenetic protein-2 decreases microRNA-30b and microRNA-30c to promote vascular smooth 
muscle cell calcification
(125) 96 Down-regulation of miR-96 by bone morphogenetic protein signalling is critical for vascular smooth muscle 
cell phenotype modulation
(126) 205 MicroRNA-205 regulates the calcification and osteoblastic differentiation of vascular smooth muscle cells
(127) 133a MiR-133a modulates osteogenic differentiation of vascular smooth muscle cells
(128) 4530, 133b Differential expression of microRNAs in severely calcified carotid plaques
(129) 26a MiR-26a regulates vascular smooth muscle cell calcification in vitro through targeting CTGF
(130) 297a MicroRNA-297a regulates vascular calcification by targeting fibroblast growth factor 23
(131) 223 Inorganic phosphate accelerates the migration of vascular smooth muscle cells: Evidence for the 
involvement of miR-223
(132) 34b + 34c MicroRNA-34b/c inhibits aldosterone-induced vascular smooth muscle cell calcification via a SATB2/Runx2 
pathway
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that after wire injury of the femoral artery about 50% of newly formed 
VSMCs were derived from adventitial Gli1+ cells (94). Furthermore, 
FACS isolated adventitial Gli1+ MSC could be differentiated into 
calponin+, αSMA+, smoothelin+ VSMCs in vitro (94). This data 
indicates that adventitial Gli1+ MSC are indeed progenitors of VSMCs.
The role of adventitial Gli1+ MSC in vascular calcification was 
studied in triple transgenic Gli1CreER; tdTomato, ApoEKO mice. 
Mice were pulsed with tamoxifen in order to genetically tag Gli1+ 
cells by expression of the bright red fluorochrome tdTomato. Mice 
were subjected to either subtotal nephrectomy and western diet or 
sham surgery with standard chow. Interestingly, a continuous low 
frequency migration of Gli1+ cells into the media during aging 
in the sham group was observed. Gli1+ cells acquired markers of 
VSMCs such as α-SMA and calponin suggesting that progenitor cells 
continuously replace lost VSMCs during aging (94). Importantly, 
these data indicate a great migration of Gli1+ cells into the media 
and neointima during chronic injury and atherosclerosis. Multiple 
co-staining experiments indicated that adventitial Gli1+ cells first 
differentiated into contractile VSMCs (α-SMA+, calponin+) and 
then underwent a phenotypic switching with loss of contractile 
VSMC markers and acquisition of synthetic VSMC markers such as 
Tropomyosin alpha 4 (TPM4) and non-muscle myosin heave chain 2b 
(nmMHC2b) (94). Importantly, during vascular calcification a high 
percentage of Gli1+-derived cells acquired nuclear expression of the 
transcription factor Runx2 indicating differentiation into osteoblast-
like cells. Imaging experiments after injection of a fluorochrome 
conjugated bisphosphonate (Osteosense) indicated that calcified areas 
showed intense accumulation of tdTomato+ cells. Importantly, genetic 
ablation of Gli1+ cells in triple transgenic Gli1CreER; iDTR; ApoEKO 
mice before onset of CKD completely abolished vascular calcification 
in both the intima and media. Thus, clearly demonstrating that 
adventitial Gli1+ cells are important progenitors of synthetic VSMCs 
and osteoblast-like cells in the vascular wall. Adventitial Gli1+ cells 
can be considered an important therapeutic target in vascular 
calcification. Interestingly, we observed a Shh domain in the adventitia 
of human arteries where endothelial cells of vasa vasorum stained 
positive for Shh, whereas surrounding cells showed Gli1 expression. 
Further staining experiments in calcified human arteries showed 
intense Gli1 expression around calcified intima and media areas.
While these data clearly demonstrate an important role of 
adventitial MSC-like cells in vascular calcification there are still 
various open questions that need to be answered (Figure 3). It is 
unclear whether the Gli1+ population is a homogenous progenitor 
population or whether several subpopulations exist. Single-cell qPCR 
analysis of sorted Gli1+ cells for reported markers of adventitial 
progenitors indicates heterogeneity with three distinct subpopulations 
(unpublished data). Thus, it will be important to differentiate between 
these subpopulations. Next, it remains elusive as to whether Gli1-
expressing cells of human arteries may also secrete EVs and thereby 
contribute to vascular calcification. Finally, while our data clearly 
indicates migration and differentiation of Gli1+ cells during acute 
injury repair and chronic disease progression, the underlying 
molecular pathways that activate migration and differentiation of 
the progenitor population remain obscure. It is currently not known 
whether EVs are involved in migration and differentiation of MSCs. 
Further, we must await as to whether adventitial Gli1+ cells produce 
EVs or interact with EVs from other cells such as platelets, immune 
cells and VSMCs. Experiments in myelofibrosis demonstrated that 
a malignant hematopoietic clone in particular megakaryocytes can 
activate Gli1+ cells to leave their niche partly by CXCL4 release (142). 
Thus, involvement of platelet and cellular EVs might be an explanation 
for activation and migration of Gli1+ cells. Further studies are needed 
to answer whether EVs are involved in Gli1+ cell recruitment and 
differentiation.
ConCluSion
The biology of vascular disease and calcification is complex and still 
poorly understood with respect to cause and consequence of players 
and pathways, and thus complexity increases continuously by ongoing 
elucidation of novel players and pathways. A subset of EVs act as 
mediators of cell-induced extracellular matrix calcification in the 
pathogenesis of cardiovascular disease. On the other hand, it has 
become evident that platelet and cellular vesicles play an important 
role in cellular communication. Whether such communication from 
platelet EVs can transpire through endothelial cells to the media 
FiguRe 3  | Calcifying EVs and Gli1+ Progentior Cells.
Schurgers et al.
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